Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Enveric Biosciences, Inc. ENVB

Healthcare  —  Biotechnology
1.50 (0.05) (3.23%) as of 25 Sep
Market cap
$6.9M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Enveric Biosciences, Inc. (ENVB) Business Profile

Updated before January 2025

Company Overview

Enveric Biosciences, Inc. (NASDAQ: ENVB) is a biotechnology company focused on developing innovative mental health treatments and therapies. Founded in 2019 and headquartered in Naples, Florida, Enveric aims to address unmet medical needs in the mental health and central nervous system (CNS) space. The company leverages cutting-edge science, including psychedelic-derived molecules and cannabinoid-based therapies, to create novel solutions for patients suffering from mental health disorders.

Enveric’s leadership team comprises experienced professionals in the biotechnology and pharmaceutical industries. Joseph Tucker, Ph.D., serves as the Chief Executive Officer, bringing extensive expertise in drug development and commercialization. The company’s leadership is committed to advancing its pipeline of therapies and driving innovation in the mental health sector.

Core Business Segments

Enveric Biosciences operates primarily in the biotechnology and pharmaceutical sectors, with a focus on mental health and CNS disorders. The company’s core business segments include:

Psychedelic-Derived Therapies

Enveric is at the forefront of developing therapies derived from psychedelic compounds. These therapies are designed to address mental health conditions such as anxiety, depression, and post-traumatic stress disorder (PTSD). The company’s proprietary platform, Psybrary™, is a library of psychedelic-inspired molecules that serve as the foundation for its drug development efforts.

Cannabinoid-Based Therapies

In addition to psychedelics, Enveric is exploring the therapeutic potential of cannabinoids. These therapies target conditions such as cancer-related distress and other CNS disorders. By combining cannabinoids with advanced drug delivery systems, Enveric aims to enhance the efficacy and safety of its treatments.

Drug Development Pipeline

Enveric’s robust pipeline includes preclinical and clinical-stage programs focused on mental health and CNS disorders. Key programs include:

  • EV104: A cannabinoid-based therapy targeting cancer-related distress.
  • EV101: A psychedelic-derived therapy for anxiety and depression.

Business Model

Enveric Biosciences operates on a research-driven business model. The company invests heavily in R&D to develop innovative therapies that address unmet medical needs. Revenue generation is expected to come from licensing agreements, partnerships with pharmaceutical companies, and eventual commercialization of its drug candidates. Enveric also collaborates with academic institutions and research organizations to accelerate its drug development efforts.

The company’s approach integrates advanced technologies, such as artificial intelligence (AI) and machine learning, to optimize drug discovery and development. By leveraging these tools, Enveric aims to reduce development timelines and bring therapies to market more efficiently.

Strategic Direction

Enveric Biosciences is focused on becoming a leader in the mental health and CNS therapeutic space. Its strategic priorities include:

  • Pipeline Expansion: Enveric plans to advance its existing drug candidates through clinical trials while exploring new therapeutic areas.
  • Partnerships and Collaborations: The company seeks to establish strategic partnerships with pharmaceutical companies and research institutions to enhance its R&D capabilities.
  • Sustainability Goals: Enveric is committed to sustainable practices in its operations, including ethical sourcing of raw materials and minimizing its environmental footprint.
  • Global Reach: The company aims to expand its presence in international markets, targeting regions with high demand for mental health therapies.

Competitive Landscape

Enveric Biosciences operates in a highly competitive industry, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • COMPASS Pathways: A leader in psychedelic-based therapies for mental health disorders.
  • MindMed: Focused on developing psychedelic-inspired treatments for anxiety and addiction.
  • GW Pharmaceuticals: A pioneer in cannabinoid-based therapies.

Despite the competition, Enveric differentiates itself through its dual focus on psychedelics and cannabinoids, as well as its proprietary Psybrary™ platform.

Risk Factors

Enveric Biosciences faces several risks that could impact its operations and financial performance:

  • Regulatory Challenges: The development and approval of psychedelic and cannabinoid-based therapies are subject to stringent regulatory requirements.
  • Market Dependence: The company’s success depends on the commercial viability of its drug candidates.
  • Supply Chain Disruptions: Enveric relies on a global supply chain for raw materials and manufacturing, making it vulnerable to disruptions.
  • Competition: The biotechnology sector is highly competitive, with many companies vying for market share in the mental health space.

Recent Developments

Enveric has made significant strides in advancing its pipeline and corporate strategy. Recent developments include:

  • Psybrary™ Expansion: The company has added new psychedelic-inspired molecules to its Psybrary™ platform, enhancing its drug discovery capabilities.
  • Partnerships: Enveric has entered into collaborations with leading research institutions to accelerate the development of its therapies.
  • Corporate Restructuring: The company recently streamlined its operations to focus on its core business areas, improving efficiency and reducing costs.

Global developments, such as increased awareness of mental health issues and regulatory changes favoring psychedelic therapies, have positively impacted Enveric’s growth prospects.

Investment Considerations

Investors considering Enveric Biosciences should weigh the following factors:

Strengths

  • Innovative Pipeline: Enveric’s focus on psychedelics and cannabinoids positions it as a leader in the mental health therapeutic space.
  • Experienced Leadership: The company’s management team has a proven track record in drug development and commercialization.
  • Growing Market: The global mental health market is expanding, providing significant growth opportunities for Enveric.

Risks

  • Regulatory Hurdles: The approval process for psychedelic and cannabinoid-based therapies is complex and time-consuming.
  • Financial Uncertainty: As a pre-revenue company, Enveric relies on external funding to sustain its operations.
  • Market Competition: The company faces intense competition from both established players and emerging startups.

Conclusion

Enveric Biosciences is well-positioned to capitalize on the growing demand for innovative mental health therapies. With a robust pipeline, experienced leadership, and a focus on cutting-edge science, the company has the potential to become a leader in the biotechnology sector. However, investors should carefully consider the risks associated with regulatory challenges and market competition. Overall, Enveric’s strategic direction and commitment to innovation make it a compelling player in the mental health therapeutic space.